Lior Shaltiel
Vorstandsvorsitzender bei NUREXONE BIOLOGIC INC.
Vermögen: 198 475 $ am 30.04.2024
Aktive Positionen von Lior Shaltiel
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| NUREXONE BIOLOGIC INC. | Direktor/Vorstandsmitglied | 15.06.2022 | - |
| Vorstandsvorsitzender | 01.04.2021 | - | |
NurExone Biologic Ltd.
 NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022. | Direktor/Vorstandsmitglied | 01.04.2021 | - |
| Vorstandsvorsitzender | 01.04.2021 | - |
Karriereverlauf von Lior Shaltiel
Statistik
International
| Israel | 2 |
| Kanada | 2 |
Operativ
| Director/Board Member | 2 |
| Chief Executive Officer | 2 |
Sektoral
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NUREXONE BIOLOGIC INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
NurExone Biologic Ltd.
NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022. | Health Technology |
- Börse
- Insiders
- Lior Shaltiel
- Erfahrung
